NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC)
BREAST（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要